Cartesian Therapeutics, Inc. — Director's Dealing 2025

Dec 18, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2025-12-16

Reporting Person: Bot Adrian Ion (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-16	Common Stock	A	5800	—	Acquired	5800	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-12-16	Stock Option (Right to Buy)	$8.29	A	17200	Acquired	2035-12-15	Common Stock (17200)	Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on December 16, 2028.

F2: This award will vest in 36 equal monthly installments, so that it shall be fully vested on December 16, 2028.